Pregnancy and lactation-associated osteoporosis (PLO) is a rare but serious bone loss condition that occurs during late pregnancy or breastfeeding, causing fractures in young women. According to Gram Research analysis, a case report documents one patient whose bone loss improved with vitamin D, teriparatide medication, and lifestyle changes, monitored using REMS—a safe ultrasound technology that avoids radiation exposure. This suggests REMS could become an important tool for detecting and tracking bone loss in pregnant and breastfeeding women, though larger studies are needed to confirm its effectiveness.
A young woman developed severe bone loss during pregnancy, a rare condition called pregnancy and lactation-associated osteoporosis (PLO). According to Gram Research analysis, doctors treated her with vitamin D, a bone-building medication called teriparatide, and lifestyle changes. They used a new ultrasound technology called REMS to safely monitor her bone health without radiation exposure. This case report suggests that REMS could become an important tool for detecting and tracking bone loss in pregnant and breastfeeding women, offering a safer alternative to traditional X-ray bone scans.
Key Statistics
A 2026 case report published in Endocrinology, Diabetes & Metabolism Case Reports documented a young woman with pregnancy and lactation-associated osteoporosis who developed multiple vertebral fractures during pregnancy and showed bone density improvement with vitamin D, teriparatide, and lifestyle modifications.
Research reviewed by Gram shows that REMS (radiofrequency echographic multi-spectrometry), a novel ultrasound-based bone monitoring technology, successfully tracked bone mineral density changes in a patient with pregnancy-associated osteoporosis without using ionizing radiation.
A 2026 case report suggests that REMS technology could represent a significant advancement in managing pregnancy and lactation-associated osteoporosis by providing safe, radiation-free monitoring for pregnant and breastfeeding women at risk of bone loss.
The Quick Take
- What they studied: Whether a new ultrasound technology called REMS could help doctors detect and monitor bone loss in pregnant and breastfeeding women
- Who participated: One young woman who developed severe bone loss (multiple spine fractures) during her pregnancy
- Key finding: The patient’s bone density improved after treatment with vitamin D, teriparatide, and lifestyle changes, and REMS successfully tracked these improvements without using radiation
- What it means for you: If you’re pregnant or breastfeeding and experience bone pain or fractures, ask your doctor about bone density screening. REMS may offer a safer monitoring option than traditional X-rays, though more research is needed to confirm its effectiveness in larger patient groups
The Research Details
This is a case report, which means doctors documented the medical history and treatment of one patient with an unusual condition. The patient was a young woman who developed pregnancy and lactation-associated osteoporosis (PLO)—a rare type of bone loss that happens during late pregnancy or while breastfeeding. The doctors treated her with three approaches: vitamin D supplements to improve calcium absorption, teriparatide (a medication that stimulates new bone formation), and lifestyle modifications like exercise and proper nutrition. Throughout her treatment, they used REMS technology to measure her bone density at different time points.
REMS stands for radiofrequency echographic multi-spectrometry. Unlike traditional bone density scans (DEXA scans) that use X-rays, REMS uses ultrasound waves—the same safe technology used in pregnancy ultrasounds. This makes it particularly valuable for monitoring pregnant and breastfeeding women who should avoid radiation exposure.
The doctors documented how the patient’s bone density changed over time and whether REMS could reliably track these changes. This type of case report is valuable because it describes a rare condition and demonstrates a new monitoring approach that other doctors might consider using with their own patients.
Case reports are important stepping stones in medical research. They help doctors recognize rare conditions, develop better treatment approaches, and test new diagnostic tools. PLO is poorly understood and has no established treatment guidelines, so documenting successful cases helps the medical community learn. Testing REMS in this case is significant because it’s a radiation-free alternative to traditional bone scans, which is crucial for pregnant and breastfeeding women who need repeated monitoring but want to avoid radiation exposure.
This is a single case report, which is the lowest level of scientific evidence. It describes what happened to one patient, but we cannot conclude that the same treatment will work for everyone with PLO. The findings are valuable for generating ideas and alerting doctors to a new monitoring tool, but larger studies with many patients are needed to confirm REMS’s effectiveness. The case does show that REMS can measure bone density changes, but we don’t yet know if it’s as accurate as traditional methods or how it compares in different patient populations.
What the Results Show
The patient presented with multiple fractures in her spine (vertebral fractures) discovered during late pregnancy. Initial diagnosis confirmed she had pregnancy and lactation-associated osteoporosis, a condition where bone density drops dangerously during pregnancy or breastfeeding. The underlying cause of PLO is complex and not fully understood, but it appears to involve hormonal changes and calcium demands during pregnancy and milk production.
After starting treatment with vitamin D, teriparatide, and lifestyle modifications, the patient’s bone mineral density improved over the monitoring period. The REMS ultrasound technology successfully tracked these improvements, showing measurable increases in bone density at follow-up assessments. The patient tolerated all treatments well without serious side effects.
The case demonstrates that REMS can be used to monitor bone density changes in young women with PLO. Unlike traditional DEXA scans that use ionizing radiation, REMS uses ultrasound, making it safe for repeated use in pregnant and breastfeeding patients. The technology provided clear measurements that helped doctors assess whether treatment was working.
The case highlights that PLO can cause severe complications, including multiple spine fractures that could affect long-term quality of life. The combination of vitamin D supplementation, bone-building medication (teriparatide), and lifestyle changes appeared to be an effective treatment approach for this patient. The successful use of REMS suggests it could become a standard monitoring tool for women at risk of PLO, though this needs confirmation in larger studies.
PLO is a rare condition with limited research and no established clinical guidelines for diagnosis or treatment. This case report adds to the small body of literature on PLO management. The use of REMS is novel in this context—previous monitoring of bone loss typically relied on DEXA scans (X-ray based) or clinical assessment. This case suggests REMS could fill an important gap by offering radiation-free monitoring, which aligns with the medical principle of minimizing radiation exposure in pregnant and breastfeeding women.
This is a single case report describing one patient’s experience. We cannot generalize these results to all women with PLO because individual responses to treatment vary. The study doesn’t compare REMS to traditional bone density measurements, so we don’t know if REMS is equally accurate. We also don’t know the long-term outcomes—whether the patient’s bone density remained stable years after treatment ended. Finally, the underlying causes of PLO remain unclear, so we cannot predict who will develop this condition or how to prevent it. Larger studies with many patients are needed to confirm REMS’s role in PLO management.
The Bottom Line
Women who experience bone pain, fractures, or are at high risk for bone loss during pregnancy or breastfeeding should discuss screening with their healthcare provider (moderate confidence—based on one case). If bone loss is detected, treatment with vitamin D, bone-building medications, and lifestyle modifications may help (moderate confidence). REMS may be a useful monitoring tool for tracking bone density during treatment, though more research is needed to confirm its accuracy compared to standard methods (low confidence—based on one case).
Pregnant women and breastfeeding mothers should be aware of PLO, especially if they experience unexplained bone pain or fractures. Healthcare providers managing high-risk pregnancies should consider bone density screening. Radiologists and bone specialists should know about REMS as a potential radiation-free monitoring option. Women should NOT assume they will develop PLO—it’s rare—but those with risk factors (prolonged breastfeeding, inadequate calcium intake, vitamin D deficiency) should discuss prevention with their doctor.
In this case, bone density improvements were measurable over the treatment period, though the exact timeline wasn’t specified in the report. Typically, bone-building medications like teriparatide show effects over months to years. Women should expect ongoing monitoring rather than quick fixes. Full recovery of bone density may take 1-2 years or longer, depending on the severity of initial bone loss.
Frequently Asked Questions
Can pregnancy cause permanent bone loss?
Pregnancy can cause temporary bone loss, especially during late pregnancy and breastfeeding. A 2026 case report shows that with proper treatment (vitamin D, bone-building medications, and exercise), bone density can improve. However, a rare condition called pregnancy and lactation-associated osteoporosis causes severe bone loss with fractures that requires medical treatment.
What is REMS technology and is it safe during pregnancy?
REMS (radiofrequency echographic multi-spectrometry) is an ultrasound-based bone density measurement tool—the same safe technology used in pregnancy ultrasounds. Unlike X-ray bone scans, REMS uses no radiation, making it ideal for monitoring pregnant and breastfeeding women. A 2026 case report demonstrates it can successfully track bone density changes.
How is pregnancy-related bone loss treated?
Treatment typically includes vitamin D supplementation to improve calcium absorption, bone-building medications like teriparatide, and lifestyle modifications including weight-bearing exercise and adequate nutrition. A 2026 case report shows this combination approach improved bone density in a patient with pregnancy and lactation-associated osteoporosis.
Who is at risk for osteoporosis during pregnancy?
Pregnancy and lactation-associated osteoporosis is rare, but risk factors include prolonged breastfeeding, inadequate calcium or vitamin D intake, and certain medical conditions. Most pregnant women don’t develop this condition. If you experience bone pain or fractures during pregnancy, discuss screening with your healthcare provider.
Should I get a bone density scan while pregnant?
Traditional bone density scans use X-rays and should be avoided during pregnancy. A 2026 case report suggests REMS ultrasound technology could be a safer alternative for monitoring bone health in pregnant women, though discuss with your doctor whether screening is necessary based on your individual risk factors.
Want to Apply This Research?
- Track calcium and vitamin D intake daily (target: 1000-1200 mg calcium, 600-800 IU vitamin D), weight-bearing exercise minutes per week (target: 150 minutes), and any bone pain or unusual symptoms. Log these weekly to identify patterns.
- Set daily reminders for vitamin D and calcium supplements. Schedule 30 minutes of weight-bearing exercise (walking, dancing, light strength training) at least 5 days per week. Track these activities in the app to build consistency and share progress with your healthcare provider.
- Create a quarterly check-in reminder to review bone health metrics with your doctor. Log any new symptoms, medication changes, or lifestyle modifications. Use the app to prepare for bone density scans by documenting your treatment timeline and any questions for your healthcare provider.
This article describes a single case report and should not be used for self-diagnosis or self-treatment. Pregnancy and lactation-associated osteoporosis is a rare medical condition requiring professional diagnosis and management. If you experience bone pain, fractures, or other concerning symptoms during pregnancy or breastfeeding, consult your healthcare provider immediately. REMS technology is not yet standard clinical practice for all patients and should only be used under medical supervision. Always discuss bone health screening, supplementation, and treatment options with your obstetrician or healthcare provider before starting any new regimen. This information is educational and does not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.